The main mechanism of IFX is to neutralize the biological activity of TNF by binding with high affinity to the soluble and transmembrane forms of TNF and to inhibit binding of TNF with its receptors (p55/p75 subunits) [9], which came up with a new approach for the treatment of active CD with very inspiring results in the field of efficacy and safety [10]. Here, TNF is linked to Cowden disease.